
Please try another search
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is based in Tampa, Florida.
Name | Age | Since | Title |
---|---|---|---|
Suneel K. Gupta | 67 | - | Member of Scientific Advisory Board |
Narasimhan Mani | - | 2024 | President, Co-CEO & Director |
Lawrence S. Olanoff | 73 | - | Member of Scientific Advisory Board |
Wantanee Phuapradit | - | - | Member of Scientific Advisory Board |
Shankar Hariharan | 68 | 2024 | Founder, Co-CEO & Executive Chairman |
Donald G. Fell | 79 | 2014 | Independent Director |
Subbarao Jayanthi | 54 | 2024 | Independent Director |
Mayur Mansukhlal Doshi | 62 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review